One Capital Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

One Capital Management’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$737K	Sell	9,314 -373	-4%	-$30.1K	0.02%	337
2025 Q4	$796K	Sell	9,687 -513	-5%	-$39.7K	0.02%	325
2025 Q3	$713K	Sell	10,200 -2,630	-20%	-$178K	0.02%	322
2025 Q2	$822K	Sell	12,830 -11,033	-46%	-$683K	0.03%	277
2025 Q1	$1.51M	Sell	23,863 -276	-1%	-$18.6K	0.05%	189
2024 Q4	$1.61M	Sell	24,139 -214	-0.9%	-$14.8K	0.05%	173
2024 Q3	$1.7M	Sell	24,353 -1,049	-4%	-$72.6K	0.05%	179
2024 Q2	$1.65M	Buy	25,402 +6,137	+32%	+$389K	0.06%	179
2024 Q1	$1.25M	Sell	19,265 -534	-3%	-$34.7K	0.05%	169
2023 Q4	$1.3M	Buy	+19,799	New	+$1.15M	0.05%	168

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

One Capital Management's PBE Position: Q1 2026 in Review

One Capital Management reduced its Invesco Biotechnology & Genome ETF (PBE) stake by 3.9% in Q1 2026, selling an estimated $30.1K and leaving 9,314 shares worth $737K. The position accounts for 0.02% of the portfolio, ranked #337.

One Capital Management first reported a position in PBE in Q4 2023 and has held it in 10 quarters since. The position peaked at $1.7M in Q3 2024. 100 funds tracked by Wall St. Rank hold PBE as of Q1 2026.

One Capital Management held 9,314 shares of Invesco Biotechnology & Genome ETF worth $737K as of Q1 2026.
One Capital Management sold 373 Invesco Biotechnology & Genome ETF shares in Q1 2026, an estimated $30.1K.
Invesco Biotechnology & Genome ETF made up 0.02% of One Capital Management's portfolio in Q1 2026, its #337 holding.
One Capital Management first reported a position in Invesco Biotechnology & Genome ETF in Q4 2023 and has held it in 10 quarters since.
One Capital Management's Invesco Biotechnology & Genome ETF position peaked at $1.7M in Q3 2024.
100 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2026.

Based on One Capital Management's 13F filing for Q1 2026, filed 13 May 2026.